Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Mol Cancer Ther. 2019 Mar 29;18(5):969–979. doi: 10.1158/1535-7163.MCT-18-0770

Figure 3. The inhibition of PI3K and BRCA1 in the presence of EP-100.

Figure 3.

(A) A network of downregulated/upregulated proteins in combination group compared to olaparib group was determined using Netwalker analysis. (B) Expression of PI3K/AKT, p-PI3K/p-AKT, PARP, Cleaved PARP, BRCA1, BRCA2, and RAD 51 after treatment. (C) Expression and localization of GnRH-R in BRCA1 mutant (BRCA1m) COV362 and MDA-MB-436 cells and BRCA2 mutant (BRCA2m) KURAMOCHI cells. The fixed cells without permeabilization (left panels) were visualized using confocal microscopy (TCS SP5 MP; Leica Microsystems, Buffalo Grove, IL). The fixed and permeabilized cells (right panels) were visualized using a laser-scanning microscope (Leica). (Scale bar: 50 μM). (D) cell viability of COV362, MDA-MB-436, and KURAMOCHI cells after treatment with EP-100, olaparib, or EP-100 plus olaparib for 72 h. (E) CI values are shown as in Fa-CI plots.